Ascentage Pharma CEO Dr. Yang on IPO
Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual ...
IPO market comeback: How recent major US listings fared
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
3FPX, ARM : IPO Rebound In 2025? Here's What's Fueling The Boom,...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
2024 Year In Review: IPO Market Overview
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut ...
Denta Water and Infra IPO day 3: GMP, subscription status to review. Should you apply as bidding ends today?
According to market observers, shares of the company are available at a premium of ₹151 in the grey market today ...
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
FierceBiotech8h
‘A really rational IPO environment’: What does it takes for a biotech to go public now?
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...